Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065611 | 0.86 | LTB4R (0.51) | LTB4RALDH1A1 | |
| Propionic Acid SCHEMBL28438232 | 0.78 | LTB4R (0.58) | LTB4RALDH1A1 | |
| SCHEMBL9093730 | 0.76 | LTB4R (0.51) | LTB4RALDH1A1 | |
| SCHEMBL28904223 | 0.72 | LTB4R (0.44) | LTB4RALDH1A1 | |
| SCHEMBL6064644 | 0.71 | EPHX1 (0.46) | EPHX1EPHX2ICMTALBCNR1 | |
| Nonanoate SCHEMBL30520295 | 0.71 | GPR84 (0.59) | EPHX1PDE4AALDH1A1 | |
| Decanoic Acid SCHEMBL9138144 | 0.71 | GPR84 (0.59) | EPHX1PDE4AALDH1A1 | |
| Octanoic Acid SCHEMBL26607802 | 0.71 | GPR84 (0.59) | EPHX1PDE4AALDH1A1 | |
| Stearic Acid SCHEMBL9356615 | 0.71 | GPR84 (0.59) | EPHX1PDE4AALDH1A1 | |
| Dodecanoate SCHEMBL975849 | 0.71 | GPR84 (0.59) | EPHX1PDE4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | KANEKA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1600438-A1 | PROCESSES FOR THE PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS HAVING SUBSTITUENTS AT THE 2-POSITION | KANEKA CORPORATION (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | TST, TMT1A, OSGEP | EPHX1 1356/4885EPHX2 475/4885LTB4R 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.